Giant Cell Arteritis Clinical Trial
— TOGIACOfficial title:
Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement (ToGiAC)
A French multicenter randomised and placebo-controlled study recruiting patients who present neurovascular involvement related to GCA (> 60 years) with symptomatic (stroke) or asymptomatic forms. The aim of this study is to assess the efficacy of tocilizumab to induce complete remission of GCA with cerebrovascular involvement (clinical and biological) and absence of clinical and MRI ischemic stroke recurrence at 24 weeks.
Status | Recruiting |
Enrollment | 66 |
Est. completion date | March 2024 |
Est. primary completion date | March 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years and older |
Eligibility | Inclusion Criteria: - Age > 60 years - Diagnosis of - GCA (according to ACR criteria or positive temporal artery biopsy) (de novo and/or relapse) And neurovascular involvement: - Either Ischemic stroke (including TIA) in the vertebro-basilar or carotid territory (symptomatic arterial involvement) - Either PET uptake of vertebral and/or carotid arteries (extra or intra cranial) and/or angioCT or angioMRI showing arterial involvement consistent with vasculitis (asymptomatic arterial involvement) - Inclusion should be done - within 4 weeks after the stroke concerning the "symptomatic" patients - within 4 weeks after the diagnosis of GCA (or relapse) concerning the patients with asymptomatic neurovascular involvement. - Within 14 days after starting the corticosteroids - Signed Informed Consent Form - Affiliation to social security Exclusion Criteria: Exclusion Criteria : - Other proven cause of stroke: atrial fibrillation, significant atheromatous stenosis of carotid or vertebro-basilar arteries - Contraindication to and precaution in use of tocilizumab: - Treatment with any investigational agent within 12 weeks (or 5 half-lives of the investigational drug, whichever was longer) of screening - Previous treatment with cell-depleting therapies, including investigational agents,including but not limited to Campath (alemtuzumab), anti-CD4, anti-CD5, anti-CD3, anti-CD19, and anti-CD20 - Treatment with IV gamma globulin or plasmapheresis within 24 weeks of baseline - Previous treatment with alkylating agents, such as chlorambucil, or with total lymphoid irradiation - Previous treatment with TCZ - Immunization with a live/attenuated vaccine within 4 weeks prior to baseline or simultaneously with tocilizumab treatment - Treatment with hydroxychloroquine, cyclosporine A, azathioprine, or mycophenolate mofetil (MMF) within 4 weeks of baseline - Treatment with etanercept within 2 weeks; infliximab, certolizumab, golimumab,abatacept, or adalimumab within 8 weeks; or anakinra within 1 week of baseline - Previous treatment with tofacitinib - Treatment with cyclophosphamide within 24 weeks of baseline - History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies or to prednisone - Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (including uncontrolled diabetes mellitus), psychiatric, osteoporosis/osteomalacia, glaucoma, corneal ulcers/injuries, or gastrointestinal disease - Current liver disease, as determined by the investigator - History of diverticulitis, diverticulosis requiring antibiotic treatment, or chronic ulcerative lower GI disease such as Crohn's disease, ulcerative colitis, or other symptomatic lower GI conditions that might predispose a patient to perforations - Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections (including but not limited to tuberculosis [TB] and atypical mycobacterial disease, hepatitis B and C, and herpes zoster, but excluding fungal infections of the nail beds) - Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks of screening - Active TB requiring treatment within the previous 3 years - Patients treated for TB with no recurrence within 3 years and patients treated for latent TB within 3 years were eligible. - Primary or secondary immunodeficiency (history of or currently active) - Evidence of malignant disease or malignancies diagnosed within the previous 5 years (except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that had been excised and cured) - History of alcohol, drug, or chemical abuse within 1 year prior to screening - Body weight >150 kg - Serum creatinine >1.4 mg/dL (124 µmol/L) in female patients and 1.6 mg/dL (141 µmol/L) in male patients - Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)× 3 Upper limit of normal (ULN)> - Platelet count < 100 109/L (100,000/mm3) - Hemoglobin < 85 g/L (8.5 g/dL; 5.3 mmol/L) - White blood cells <3.0 x109/L (3000/mm3) - Absolute neutrophil count < 2.0 x 109/L (2000/mm3) - Absolute lymphocyte count < 0.5 X 109/L (500/mm3) - Positive hepatitis B surface antigen or hepatitis C antibody - Contraindication to aspirin, clopidogrel, steroids use, rifampicin and/or isoniazid - Major surgery within 8 weeks prior to screening or planned major surgery within 12 months after randomization, except arterial thrombectomy if necessary for ischemic stroke - Transplanted organs (except corneal transplant performed more than 3 months prior to screening) - Inability to provide informed consent - Participation in another interventional research |
Country | Name | City | State |
---|---|---|---|
France | Saint Antoine Hospital, Neurology Unit, Assistance Publique-Hôpitaux de Paris | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris | Roche Chugai, Roche Pharma AG |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of patients in complete remission of GCA with absence of ischemic stroke recurrence at 24 weeks under tocilizumab. | Percentage of participants with complete remission of GCA, defined as an absence of clinical signs of GCA, a CRP levels less than 10 mg/l and an absence of new ischemic stroke signs at MRI realized at 24 weeks after the tocilizumab initiation | From date of treatment initiation until 24 weeks. | |
Secondary | Compare within tocilizumab and placebo groups the percentage of clinical and MRI ischemic stroke recurrence at 24 weeks | the efficacy of weekly tocilizumab on the prevention of stroke recurrence will be measured by the percentage of stroke recurrence compared to control group in patients with GCA during 52 weeks at week 4, 12, 24 and 52 | at week 4, 12, 24 and 52. | |
Secondary | The relapse-free survival | Number of patients who had relapsed as defined as major if clinical symptoms are present, or as minor in the case of isolated acute pase reactants increase | up to 52 weeks | |
Secondary | Compare within tocilizumab and placebo groups the time to remission in patients with GCA during 52 weeks. | the time to remission will be assessed in comparison with the control group in patients with GCA during 52 weeks at week 4, 12, 24 and 52 Number of days between treatment induction and signs of remission. | at week 4, 12, 24 and 52. | |
Secondary | Compare within tocilizumab and placebo groups the improvement of neurovascular radiological involvement during 52 weeks | Proportion of patient with neurovascular radiological involvement defined as angio-CT improvement of vasculitis lesions and /or improvement or disappearance of PET FDG uptake. | at week 4, 12, 24 and 52. | |
Secondary | Compare within tocilizumab and placebo groups the steroid sparing effect at 24 weeks | Cumulative steroid dose at 24 weeks | up to 24 weeks | |
Secondary | Mortality at week 4, 12, 24 and 52 | Percentages of deaths at week 4, 12, 24 and 52. | at week 4, 12, 24 and 52 | |
Secondary | Evolution of degree of disability or dependence at week 4, 12, 24 and 52 | Percentages of patients with rankin score 0-1 | at week 4, 12, 24 and 52. | |
Secondary | Percentage of Participants with Adverse Events/ serious adverse events | Percentage of participants with adverse events, treatment-related adverse events or serious adverse event as assessed by CTCAE v4.0, at week 4, 12, 24 and 52 | at week 4, 12, 24 and 52. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03812302 -
Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA)
|
Phase 2 | |
Recruiting |
NCT02257866 -
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
|
||
Recruiting |
NCT05380453 -
Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission
|
Phase 3 | |
Recruiting |
NCT02333708 -
Study of Circulating Microparticles in Giant Cell Arteritis
|
||
Completed |
NCT01450137 -
Tocilizumab for Patients With Giant Cell Arteritis
|
Phase 2 | |
Completed |
NCT03827018 -
KPL-301 for Subjects With Giant Cell Arteritis
|
Phase 2 | |
Active, not recruiting |
NCT04519580 -
Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
|
||
Recruiting |
NCT04239196 -
Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA
|
Phase 2 | |
Recruiting |
NCT06460142 -
Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
|
||
Completed |
NCT03202368 -
An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)
|
Phase 3 | |
Not yet recruiting |
NCT02523625 -
Giant Cell Arteritis: Improving Use of Ultrasound Evaluation
|
N/A | |
Completed |
NCT03285945 -
FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment
|
N/A | |
Completed |
NCT02190916 -
Vasculitis Illness Perception (VIP) Study
|
N/A | |
Recruiting |
NCT01241305 -
One-Time DNA Study for Vasculitis
|
||
Terminated |
NCT02531633 -
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
|
Phase 3 | |
Completed |
NCT03409913 -
Diagnostic Accuracy of FDG PET/CT of Cranial Arteries in GCA
|
N/A | |
Completed |
NCT03765424 -
Evaluation of Ultrasound and PET/CT in the Diagnosis and Monitoring of Giant Cell Arteritis
|
||
Completed |
NCT01910038 -
Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.
|
Phase 2 | |
Not yet recruiting |
NCT04012905 -
Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering
|
Phase 3 | |
Recruiting |
NCT06004154 -
Post-therapeutic Imaging Evaluation of Patients With Horton's Disease (Giant Cell Arteritis) (EvHortim)
|